REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 17, 2016--
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused
on improving the lives of patients by developing best-in-class medicines
that address major unmet medical needs, today announced the appointment
of David L. Szekeres as Senior Vice President of Business Development,
General Counsel and Corporate Secretary. Mr. Szekeres joins the Company
today and will report to Barry D. Quart, Pharm.D., Chief Executive
Officer of Heron.
“We are very excited that David has decided to join Heron, as he brings
over 15 years of legal and industry experience, including a strong
background in transactions,” commented Dr. Quart. “David will be a
tremendous asset to the Company and is a welcome addition to the
management team.”
Mr. Szekeres most recently served as General Counsel, Chief Business
Officer, Principal Financial Officer, and Corporate Secretary at Regulus
Therapeutics, Inc. In that role, Mr. Szekeres played a critical role in
overseeing the company’s business, financial and legal responsibilities
as it developed into a clinical-stage corporation. From March 2008
through February 2014, Mr. Szekeres served as Deputy General Counsel,
Chief Mergers and Acquisitions Counsel and Assistant Corporate Secretary
at Life Technologies Corporation. Prior to his tenure at Life
Technologies, from 2001 through 2006, Mr. Szekeres served as Corporate
Attorney at a number of law firms, including O’Melveny & Myers LLP and
Latham & Watkins LLP and prior to this, he served as Senior Associate in
Investment Banking at investment bank Robertson Stephens. Mr. Szekeres
received a B.A. degree magna cum laude from the University of
California, Irvine and a J.D. degree from Duke University School of Law.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a biotechnology company focused on improving
the lives of patients by developing best-in-class medicines that address
major unmet medical needs. Heron is developing novel, patient-focused
solutions that apply its innovative science and technologies to
already-approved pharmacological agents for patients suffering from
cancer or pain. Heron’s goal is to build on therapeutics with well-known
pharmacology by improving their tolerability and efficacy as well as
broadening their potential field of use. For more information, visit www.herontx.com.
Forward-Looking Statements
This news release contains "forward-looking statements" as defined by
the Private Securities Litigation Reform Act of 1995. Heron cautions
readers that forward-looking statements are based on management’s
expectations and assumptions as of the date of this news release and are
subject to certain risks and uncertainties that could cause actual
results to differ materially. These risks and uncertainties include, but
are not limited to, those associated with: whether the U.S. Food and
Drug Administration (FDA) completes its review within the anticipated
time period, whether the FDA approves the SUSTOL NDA as submitted or
supports as broad of a labeled indication for SUSTOL as requested, the
potential market opportunity for SUSTOL and expected timing of the
commercial launch, the progress in the research and development of
HTX-019, HTX-011 and our other programs, including the timing of
preclinical, clinical, and manufacturing activities, safety and efficacy
results from our studies that may not justify the pursuit of further
development of our product candidates, acceptance of SUSTOL and new
products generally, our financial position and our ability to raise
additional capital to fund operations, if necessary, or to pursue
additional business opportunities, strategic business alliances we may
pursue or the potential acquisition of products or technologies, and our
ability to grow our organization to sustain the commercial launch for
SUSTOL, and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission. Forward-looking
statements reflect our analysis only on their stated date, and Heron
takes no obligation to update or revise these statements except as may
be required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160317005063/en/
Source: Heron Therapeutics, Inc.
Heron Therapeutics, Inc.
Investor Relations Contact:
Jennifer
Capuzelo, 858-703-6063
Associate Director, Investor Relations
jcapuzelo@herontx.com
or
Corporate
Contact:
Barry D. Quart, Pharm D., 650-366-2626
Chief
Executive Officer